NCT06052748CompletedPhase 3
A Study to Evaluate the Efficacy and Safety of AD-223
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension
Source: ClinicalTrials.gov · Last updated 4 Apr 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of AD-223
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 502 (actual)
- First submitted
- 19 Sept 2023
- Start date
- 15 Feb 2024
- Primary completion date
- 27 Mar 2025
- Lead sponsor
- Addpharma Inc.
- Diseases
- High blood pressure
- NCT number
- NCT06052748
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 502
- From 15 Feb 2024 to the primary completion date, 27 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Orthostatic hypotension with symptom
- Other exclusions applied
Who the study is looking for
- Signed informed consent
- Other inclusions applied
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hanyang University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
Related publications
- Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.J Clin Hypertens (Greenwich) · 2026 · PMID 42130156
This page is information, not medical advice. Discuss any trial with your doctor.